Indian Urothelial Cancer market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
In India, urothelial carcinomas are often diagnosed at an early stage and have not grown into the deeper muscle layer of the bladder wall. In India, there were 18,921 new cases and 10,231 deaths with an incidence rate (per 10) of 2.4 and 0.7 in males and females, respectively, and mortality rates (per 10) as 1.3 and 0.3 in males and females, respectively, it is ranked 17th in incidence and 19th in mortality. Increasing investment in R&D activities to come up with new cancer treatment is also boosting the market for urothelial carcinoma treatment. As various awareness programs are carried out by government and non-government organizations regarding bladder cancer, and availability of novel drugs, presence of a strong pipeline, rising disease incidence, unhealthy lifestyle, and increasing awareness are driving this market.
Market Growth Drivers
Surging volume of patients suffering from urothelial cancer and high recurrence rate of patients, increasing prevalence of geriatric population, rising emergence and priority of targeted therapy among biopharmaceutical companies, rising awareness among people for early diagnosis and treatment, increasing adoption of unhealthy lifestyle of the people are some of the major as well as vital factors which will likely to augment the growth of the urothelial cancer drugs market. On the other hand, rising development of new novel drugs by pharmaceuticals companies along with surging levels of investment in research activities which will further contribute by generating massive opportunities that will lead to the growth of the urothelial cancer drugs market.